We evaluated the efficacy and safety of upadacitinib, janus kinase 1 inhibitor for atopic
dermatitis (AD) in real‐world practice. From September 2021 to March 2022, 31 patients with …

Dupilumab is a fully human monoclonal antibody that binds specifically to the shared alpha
chain subunit of the interleukin (IL)-4 and IL-13 receptors, thereby inhibiting the signalling of …

5 Hamilton JB. Male hormone stimulation is prerequisite and an incitant in common
baldness. Am J Anat 1942; 71: 451–80. 6 Moreno-Arrones OM, Becerra A, Vano-Galvan S …

Discussion The dual efficacy of dupilumab for AD and AA may be explained by their shared
immune characteristics. 2 AD is a TH 2-mediated disease with elevated IL-4, IL-5, IL-13, and …

Further studies are required to investigate the molecular mechanism underlying recurrent
AD and to determine treatment options for drug-resistant AD. Based on Hanifin-Rajka …

Introduction The efficacy and safety of upadacitinib in atopic dermatitis have been defined in
clinical trials, but long-term real-life experience, essential for clinical decision-making, is still …

Background Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory
potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy …

Atopic dermatitis (AD)(also termed atopic eczema) is a chronic inflammatory skin disease,
affecting approximately 20% of children and 1–5% of the adult population in western …

Upadacitinib, an oral Janus kinase 1 inhibitor approved for treating atopic dermatitis (AD),
can cause adverse events such as herpes zoster (HZ) and acne. We aimed to identify …

Dupilumab is the first biologic registered for the treatment of atopic dermatitis (AD). We
report a case of acute-onset monoarthritis of the ankle and generalized polyarthralgia in a …